Abstracts tagged "clinical practice and rheumatoid arthritis (RA)"

Abstract Number: 2382 • 2017 ACR/ARHP Annual Meeting
Reliability of the Biochemical Bone Markers CTX and P1NP during a TNF-Inhibitor Treatment Cycle in Patients with Rheumatoid Arthritis
Kim Holmsted¹, Niklas Rye Jørgensen² and Ole Rintek Madsen¹, ¹Center for Rheumatology and Spine Diseases & The DANBIO Registry, Copenhagen University Hospital Rigshospitalet Gentofte Glostrup, Copenhagen, Denmark, ²Dept. of Clinical Biochemistry, Rigshospitalet, Glostrup, Denmark
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of developing osteoporosis. Dual Energy X-ray Absorptiometry (DXA) with assessment of BMD is used for…
Abstract Number: 1415 • 2016 ACR/ARHP Annual Meeting
Impact of the Clinical Disease Activity Index to Treat to Target Rheumatoid Arthritis in the Ambulatory Setting
Irene Lazarus¹, Salahuddin Kazi², Alok Dwivedi³, Christopher Dodoo⁴ and Kanchan Pema⁵, ¹Internal Medicine, Texas Tech University Health Science Center, El Paso, TX, ²Rheumatology, UT Southwestern Medical Center, Dallas, TX, ³Biomedical Sciences Division of Biostatistics and Epidemiology, Texas Tech University Health Sciences Center, El Paso, TX, ⁴Texas Tech University Health Sciences Center, El Paso, TX, ⁵Internal Medicine/Rheumatology, Texas Tech University Health Science Center, El Paso, TX
Background/Purpose: Since 2008 the Center for Medicare and Medicaid Services (CMS) has been in the process of changing patient care to quality-valued healthcare. In order…
Abstract Number: 2531 • 2016 ACR/ARHP Annual Meeting
Impact of Participation in the Adalimumab (Humira) Patient Support Program on Functional and Clinical Outcomes Among Patients with Rheumatoid Arthritis: Passion Study
Filip van Den Bosch¹, Andrew Östör², Siegfried Wassenberg³, Jaclyn K. Anderson⁴, Naijun Chen⁵, Chen Wang⁴, Vishvas Garg⁵ and Jasmina Kalabic⁶, ¹Rheumatology, Ghent University Hospital, Gent, Belgium, ²Addenbrooke's Hospital, Cambridge, United Kingdom, ³Rheumazentrum, Ratingen, Germany, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Inc, North Chicago, IL, ⁶AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Patients (pt) with Rheumatoid arthritis (RA) who are treated with adalimumab (ADA) are offered a Patient Support Program (PSP) with variety of services. To…
Abstract Number: 3092 • 2016 ACR/ARHP Annual Meeting
Predictive Factors for Better Outcome of Switching of Biologics for Patients with Rheumatoid Arthritis in Daily Clinical Practice
Kazuyoshi Saito¹, Kazuhisa Nakano², Shingo Nakayamada³, Satoshi Kubo⁴, Ippei Miyagawa¹, Shigeru Iwata⁵ and Yoshiya Tanaka⁶, ¹University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The First department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁵First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Eight biologics have been approved for rheumatoid arthritis (RA) in Japan. However, little is known regarding what to do when patients have an inadequate…
Abstract Number: 548 • 2015 ACR/ARHP Annual Meeting
Comparison of Dose Escalation and Co-Therapy Intensification Between Patients with Rheumatoid Arthritis Initiating Biologic Treatment with Etanercept, Adalimumab and Infliximab
J Carter Thorne¹, Gilles Boire², Andrew Chow³, Kirsten Garces⁴, Fang Liu⁵, Melanie Poulin-Costello⁶, Valery Walker⁵ and Boulos Haraoui⁷, ¹Southlake Regional Health Centre, Newmarket, ON, Canada, ²Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ³Credit Valley Rheumatology, Mississauga, ON, Canada, ⁴Amgen Canada Inc, Mississauga, ON, Canada, ⁵Optum, Burlington, ON, Canada, ⁶Amgen Canada Inc., Mississauga, ON, Canada, ⁷Institut de rhumatologie de Montréal, Montreal, QC, Canada
Background/Purpose: The individual response to anti-TNFs etanercept (ETA), infliximab (INF) and adalimumab (ADA) in rheumatoid arthritis (RA) may vary. Options for managing inadequate response include…
Abstract Number: 1631 • 2015 ACR/ARHP Annual Meeting
Adverse Events to Biologic Agents in Elderly Patients with Rheumatoid Arthritis: Cohort with 13 Years of Follow-up
Zulema Rosales^1,2, Leticia Leon¹, Alejandro Gomez-Gomez², Lucía Arietti², Esperanza Pato Cour², José Luis Fernández Rueda¹, Juan A Jover² and Lydia Abasolo¹, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: After more than a decade using biological agents (BA), is widely known their efficacy in the treatment of Rheumatoid Arthritis (RA) and their relationship…
Abstract Number: 2759 • 2015 ACR/ARHP Annual Meeting
Long-Term Survival of Biological Therapy in Rheumatoid Arthritis Elderly Patients in Clinical Practice
Cristina Lajas¹, Alejandro Gomez-Gomez¹, Luis Rodriguez-Rodriguez², Leticia Leon², Cristina Vadillo¹, Dalifer Freites Núñez¹, Pilar Macarrón¹, José María Leal Pozuelo², Juan A Jover¹ and Lydia Abasolo², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: With the increasingly widespread use of biological agents (BA), a thorough knowledge of their long-term behavior in clinical practice is fundamental. The purpose of…
Abstract Number: 474 • 2014 ACR/ARHP Annual Meeting
Renacer Study: Assessment of 12-Month Efficacy and Safety of 168 Certolizumabpegol Rheumatoid Arthritis Treated Patients from a Multicenter Retrospective National Study in Spain
Vicente Torrente-Segarra¹, Ana Urruticoechea², Héctor Corominas¹, Amalia Sánchez³, Juan Víctor Tovar⁴, Alejandro Muñoz⁵, Anna Martínez⁶, José Antonio González⁴, Manuel Fernández⁷ and Noelia Vázquez on behalf of RENACER Study Group⁸, ¹Hospital General Hospitalet-Sant Joan Despí Moisès Broggi, Hospitalet Llobregat, Barcelona, Spain, ²Hospital de Can Mises, Ibiza, Spain, ³Hospital Universitario Lucus Augusti, Lugo, Spain, ⁴Hospital General Universitario de Elche, Alicante, Spain, ⁵Hospital Universitario de Valme, Sevilla, Spain, ⁶Hospital La Ribera, Alzira, Valencia, Spain, ⁷Hospital Universitario de Guadalajara, Guadalajara, Spain, ⁸Hospital Universitario de Ceuta, Ceuta, Spain
Background/Purpose: There's scant data of CertolizumabPEGol (CZP) in clinical practice. Study goal: assess efficacy and safety of CZP in RA patients at 3, 6,12-month (m), and…
Abstract Number: 114 • 2014 ACR/ARHP Annual Meeting
Treat-to-Target (T2T) and Measuring Outcomes in RA Care: a 2014 Longitudinal Survey of US Rheumatologists
John J. Cush¹ and Jeffrey R. Curtis², ¹Baylor Research Institute and Baylor University Medical Center, Dallas, TX, ²University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL
Background/Purpose: Changes in US rheumatologic practice for rheumatoid arthritis (RA) patients in the past decade have been influenced by novel therapies, increasing disease metric use…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].